← Eichor
Study identifier: NCT06615609 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients

Condition: Post Coronary Artery Bypass Grafting · Hypertension · Diabetes Mellitus  ·  Sponsor: China National Center for Cardiovascular Diseases

PhaseNA
Planned participants536
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to evaluate the effect of an AI-assisted "Smart family doctor" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-CABG (coronary artery bypass grafting) patients or post-PCI (percutaneous coronary intervention) patients. A randomized controlled trial design will be used, involving approximately 5-10 hospitals and 536 participants. Eligible participants are adults aged 18 or older, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.

This description comes directly from the study's public registry record.

Talk to the study team

Lihua Zhang Zhang, PhD  ·  8601060866780  ·  zhanglihua@fuwai.com

Always discuss trial participation with your own doctor first.

Locations (1)

Xinjiang's First Affiliated Hospital of medical universityÜrümqi, Xinjiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06615609